Metformina Ciclum (Metformin Hydrochloride)

Metformin primarily activates AMP‑activated protein kinase (AMPK), which suppresses hepatic glucose production and enhances peripheral glucose uptake. By reducing liver‑derived glucose and improving insulin sensitivity in muscle and fat tissue, it helps lower overall blood sugar levels.

The exact dose of Metformina Ciclum is determined by the prescribing clinician based on the individual’s renal function, glycaemic targets, and tolerance. Dosage adjustments are made during treatment to achieve optimal blood glucose control while minimizing side effects.

Metformin crosses the placenta and is classified as a pregnancy‑category B medication in many regions, meaning it may be used when the potential benefit outweighs risk. However, safety data are limited, and the drug should only be used under close medical supervision. It is excreted in breast milk, so breastfeeding mothers should consult their physician before continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metformina Ciclum belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not stimulate insulin release, reducing the risk of hypoglycaemia. It is generally weight‑neutral or may cause modest weight loss, and it has a well‑established safety profile for long‑term cardiovascular outcomes.

Metformina Ciclum should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or near heat sources.

Metformina Ciclum is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or chew the tablets unless specifically instructed.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, liver disease, or excessive alcohol intake. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant vitamin B12 deficiency with long‑term use.

Metformina Ciclum is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or other biguanides. Caution is also advised for individuals with unstable heart failure.